Table 5 The side effects of monotherapy and combined therapy between RGC patients in SMIHigh and SMILow groups
From: Impact of skeletal muscle mass in patients with recurrent gastric cancer
Monotherapy | SMIHigh (n = 7) | SMILow (n = 16) | p value | Combined chemotherapy | SMIHigh (n = 27) | SMILow (n = 17) | p value |
|---|---|---|---|---|---|---|---|
All side effects of grade 3 or 4 | Â | Â | 0.106 | All side effects of grade 3 or 4 | Â | Â | 0.011 |
 Positive | 1 (14.3) | 8 (50.0) |  |  Positive | 10 (37.0) | 13 (76.5) |  |
 Negative | 6 (85.7) | 8 (50.0) |  |  Negative | 17 (63.0) | 4 (23.5) |  |